Fundación Jiménez Díaz -ko ikertzaileekin lankidetzan egindako argitalpenak (9)

2020

  1. Evaluation of the MD Anderson tumor score for diffuse large B-cell lymphoma in the rituximab era

    European Journal of Haematology, Vol. 104, Núm. 5, pp. 400-408

  2. New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta-2 microglobulin in patients with diffuse large B-cell lymphoma treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO)

    British Journal of Haematology, Vol. 188, Núm. 6, pp. 888-897

2018

  1. Differential prognostic impact of GELTAMO-IPI in cell of origin subtypes of Diffuse Large B Cell Lymphoma as defined by the Hans algorithm

    British Journal of Haematology, Vol. 182, Núm. 4, pp. 534-541

2017

  1. Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of β2-microglobulin yields a more accurate GELTAMO-IPI

    British Journal of Haematology, Vol. 176, Núm. 6, pp. 918-928

2013

  1. Loss of TCR-beta F1 and/or EZRIN expression is associated with unfavorable prognosis in nodal peripheral T-cell lymphomas

    Blood Cancer Journal, Vol. 3, Núm. 4

  2. NIK controls classical and alternative NF-κB activation and is necessary for the survival of human T-cell lymphoma cells

    Clinical Cancer Research, Vol. 19, Núm. 9, pp. 2319-2330

2010

  1. Amolecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma

    Blood, Vol. 116, Núm. 8

2001

  1. The molecular basis of 3-methylcrotonylglycinuria, a disorder of leucine catabolism

    American Journal of Human Genetics, Vol. 68, Núm. 2, pp. 334-346

2000

  1. Structural and functional analysis of mutations in alkaptonuria

    Human Molecular Genetics, Vol. 9, Núm. 15, pp. 2341-2350